drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous chimeric antigen receptor (CAR) T-cell therapy engineered to dual-target BCMA and CD19, depleting CD19+ B cells and BCMA+ plasmablasts/long-lived plasma cells to reduce pathogenic autoantibodies and reset humoral immunity in refractory SLE.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous CAR T cells engineered to dual-target CD19 and BCMA, inducing cytolytic depletion of CD19+ B cells and BCMA+ plasmablasts/long‑lived plasma cells to reduce pathogenic autoantibodies and reset humoral immunity in refractory SLE.
drug_name
GC012F Injection
nct_id_drug_ref
NCT06530849